Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Comment by EternalPonzion Jan 12, 2021 12:20pm
213 Views
Post# 32276461

RE:RE:RE:Hi Francine

RE:RE:RE:Hi Francine
Sorry Francine, I don't buy it. Full disclosure. I sold and took loss ages ago. If you hung on good for you but now you have been given a second chance to unload - take it especially for those who took a chance and bought when was flailing around at 30 cents. The huge volume over the last month is easily explained. One just has to look at Stock Twits or Yahoo boards and the idiotic comments being spewed and it is obvious what is behind all the action. We are in an era of severe addictive behaviour. People are trading because of the 'high' it provides. If as you believe, management has relevant info regarding secondary end points why not release that info especially if it has positive diabetic potential. If the info is positive there is absolutely no downside to releasing that info, so just do it - the share price rises and you are giving yourself more leverage in negotiating a merger or sale. Since this hasn't happened yet, the only logical conclusion one can come to is they either; 1. Don't have the data yet 2. The data is not promising or, 3. They have the data and have shared with a possible merger partner which is obviously corrupt and illegal (Material info is suppose to be released in a timely fashion, not when they feel like it, which this company has never done yet and has never been punished or censured for. Which begs the question, Why does the SEC exist?). The third is unlikely though since if the data is promising that partner would have just purchased shares quietly via the market (no company is going to willingly pay more than they must). In that case, I would anticipate the share float to decrease. The continual cycling of shares leads me to believe no major player is accumulating so the stock remains in the hands of frenzied addictive traders. Bottom line, it will be very difficult to monetize this therapy in the current over populated OM3/diabetes market unless there is a clear demonstrative benefit that other drugs don't have - regardless of what you eat or what exercise you carry out. Everyone should simply endeavour to eat healthy and exercise. Yes there are some people who are genetically predisposed to high TG levels but that is a very small proportion of the population. Most people with high TG levels and diabetes can minimize these drastically with proper diet and exercise (which the phase 3 trials proved beyond doubt). From personal experience I know many who have, without taking meds. Management totally messed up the trial design but even if they hadn't, based on the previous comments, I am not so certain this would be the holy grail of TG/diabetes therapy. Unfortunately hype has a way of propelling things regardless of common sense. BITCOIN and TESLA are prime examples. How many times do you have to have the management of this company screw you over. Remember for every winner there is a loser. Management may pull off a Hail Mary to save their options but don't ride this to what you think the end point should be. Amarin is a good example of what happens if you don't make a graceful exit when one should.
<< Previous
Bullboard Posts
Next >>